1 citations
,
September 2025 in “PLoS ONE” Certain drugs may cause vitiligo, so patients should be monitored.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
March 2026 in “Bioconjugate Chemistry” Peptide-based PROTACs show promise in targeting hard-to-treat proteins, especially for cancer therapy.
2 citations
,
January 2017 in “Journal of Cosmetics, Dermatological Sciences and Applications” TrichoTech™ may help hair growth and skin repair by increasing fibroblast growth and activity.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
3 citations
,
February 2024 in “Journal of the American Academy of Dermatology” Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
April 2026 in “Future Medicinal Chemistry” PROTACs have become a breakthrough in medicine by effectively targeting and degrading specific proteins to treat diseases.
23 citations
,
December 2023 in “Skin Health and Disease” Vitiligo causes significant emotional stress in Africa, the Middle East, and Latin America, with limited treatment options available.
7 citations
,
September 2024 in “Journal of Comparative Effectiveness Research” Palbociclib generally maintains or improves quality of life in advanced breast cancer patients.